Clinical trials: Sodium-glucose Cotransporter-2 Inhibitor
Diabetes Mellitus, Cellular Senescence
Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Type 2 Diabetes
Patients with type 2 diabetes (T2D) are more prevalent with aging-related comorbidities and frailty, which leads to a shorter life expectancy than non-diabetic individuals and that this excess mortality is largely attributable to…
- Conditions
- Diabetes Mellitus, Cellular Senescence, Sodium-Glucose Transporter 2 Inhibitors
- Trial name
- NCT05975528
- Testing
- SGLT2 inhibitor, Glimepiride
- Where
- South Korea
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Diabetes Mellitus, Type 2
Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
The main objective of this trial is to evaluate whether maridebart cafraglutide is non-inferior to semaglutide in improving glycemic control in participants with type 2 diabetes (T2D) who are receiving metformin treatment, with…
- Trial name
- MARITIME-T2D-3 (NCT07866066)
- Testing
- Maridebart cafraglutide, Semaglutide
- Volunteers
- 1,300 people
- Sponsor
- Amgen
Diabetes Mellitus, Type 2
Dapagliflozin on Hyperlipidemia and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS Study)
The investigators will investigate whether dapagliflozin (FORXIGA) might improve lipoprotein metabolism as well as hyperglycemia in Japanese patients with type II diabetes mellitus whose HbA1c levels are less than 7.0% (from 20…
- Trial name
- DAPHNIS (NCT02577159)
- Testing
- Dapagliflozin
- Where
- 3 sites in Japan
- Volunteers
- 50 people
- Sponsor
- Osaka University
Cystinuria
Long Term Clinical Efficacy of Sodium-glucose Cotransporter-2 (SGLT-2) Inhibitor in Cystinurics
Cystinuria is an inherited autosomal recessive disorder of the kidney that is the result of an inability to reabsorb dibasic amino acids, including cystine, from the urine.
- Trial name
- NCT05058859
- Testing
- Dapagliflozin
- Where
- United States
- Sponsor
- University of California, San Francisco
Acute Kidney Injury
Metabolic and Renal Outcomes in Cardiac Surgery Patients Receiving SGLT2 Inhibitors
To investigate the potential of preoperative initiation (3 days) and perioperative continuation (until day 2 after surgery) of empagliflozin(sodium glucose co transporter 2 inhibitor(SGLT-2i)) 10 mg daily to reduce the acute…
- Trial name
- MERCURI (NCT06825156)
- Testing
- Empagliflozin 10 MG
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Tricuspid Regurgitation
SGLT2 Inhibitor for Severe Tricuspid Regurgitation
The purpose of this study to identify the efficacy of sodium glucose cotransporter 2 inhibitors add-on treatment on right ventricular remodeling and the amount of severe tricuspid regurgitation (TR) in patients with isolated…
- Trial name
- Reduction-TR (NCT05686616)
- Testing
- Dapagliflozin Propanediol Hydrate 12.3 mg
- Where
- South Korea
- Volunteers
- 72 people
- Sponsor
- Samsung Medical Center
Diabetic Ketoacidosis, Postoperative Care
Postoperative Euglycemic Ketoacidosis Frequency in Sodium-Glucose Cotransporter-2 Inhibitor Users
The goal of this observational study is to determine the frequency of postoperative euglycemic diabetic ketoacidosis (EDKA) in patients receiving Sodium- Glucose Cotransporter-2 (SGLT-2) inhibitors.
- Trial name
- SGLT-2I (NCT07127406)
- Where
- Turkey (Türkiye)
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Kocaeli City Hospital
Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2
Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes
Metabolic dysfunction-associated steatotic liver disease (MASLD), a condition where fat builds up in the liver, is common in patients with type 2 diabetes.
- Trial name
- NCT07269197
- Testing
- Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
- Where
- Croatia
- Volunteers
- 67 people
- Sponsor
- Josip Juraj Strossmayer University of Osijek
Diabetic Nephropathies
Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN)
The MEDiaN study aims to examine the state of fuel metabolism in participants with diabetic nephropathy (DN) before and after the use of the sodium-glucose transport protein 2 inhibitor (SGLT-2i) empagliflozin.
- Trial name
- (MEDiaN) (NCT03933956)
- Testing
- Empagliflozin 10 MG
- Where
- Singapore
- Volunteers
- 2 people
- Sponsor
- Singapore General Hospital
End Stage Renal Disease on Dialysis, Peritoneal Dialysis Complication
Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients
Empagliflozin, a new class of diabetes medication, has demonstrated a reduction in renal function decline among patients with chronic kidney disease, regardless of their diabetes status.
- Conditions
- End Stage Renal Disease on Dialysis, Peritoneal Dialysis Complication, Sodium-glucose Cotransporter-2 Inhibitor, Residual Kidney Function
- Trial name
- EMPIRIC-PD (NCT06483074)
- Testing
- Empagliflozin 10 MG
- Where
- Hong Kong
- Volunteers
- 48 people
- Sponsor
- Chinese University of Hong Kong
COVID-19
Dapagliflozin in Respiratory Failure in Patients With COVID-19
This is an international, multicenter, parallel-group, randomized, double-blind, placebo controlled, study in hospitalized adult patients with coronavirus disease 2019 (COVID-19) in the United States, Brazil, Mexico, Argentina…
- Trial name
- DARE-19 (NCT04350593)
- Testing
- Dapagliflozin 10 milligram (mg)
- Where
- 95 sites in United States, Argentina and 5 more
- Volunteers
- 1,250 people
- Sponsor
- Saint Luke's Health System
Asymptomatic Hyperuricemia
A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA
This is a randomized, placebo controlled, double-blind, 2-way crossover study conducted on asymptomatic hyperuricemic patients. The core study consists of screening period, 2 treatment periods (verinurad + febuxostat +…
- Trial name
- NCT03316131
- Testing
- Verinurad, Febuxostat, Dapagliflozin
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- AstraZeneca
Diabetes Melltius, Type 2
The Clinical Study to Assess the Effect of the Amount of Carbohydrate Intake and Meals Differing in Glycemic Index (GI) in Patients Treated With a Sodium-dependent Glucose Cotransporter 2 (SGLT2) Inhibitor
The objectives of this clinical study is to assess the effect of the amount of carbohydrate intake and meals differing in glycemic index (GI) in patients of type 2 diabetes mellitus treated with an SGLT2 inhibitor…
- Trial name
- NCT02500186
- Testing
- Luseogliflozin, Meal containing different carbohydrate ratio and GI value
- Volunteers
- 24 people
- Sponsor
- Kansai Electric Power Hospital
Type 2 Diabetes Mellitus (T2DM)
Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin
This clinical trial is studying whether combining two commonly used diabetes medications into a single pill works better than taking them separately for people with type 2 diabetes who are already on metformin.
- Trial name
- CONTROL (NCT07057479)
- Testing
- Fixed-dose combination of SGLT2 inhibitor and thiazolidinedione, Control Group 1 Intervention - SGLT2 inhibitor monotherapy, Control Group 2 Intervention - Thiazolidinedione monotherapy
- Where
- Brazil
- Sponsor
- Eurofarma Laboratorios S.A.
Type 2 Diabetes
A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
This study is a multicenter, randomized, open-label, parallel-group, phase 3 clinical trial aimed at evaluating the efficacy and safety of HDM1005 versus active comparator in subjects with Type 2 Diabetes Mellitus (T2DM)…
- Trial name
- NCT07417306
- Testing
- HDM1005 1, HDM1005 2, Mazdutide
- Where
- China
- Volunteers
- 912 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Fontan, Heart Failure
The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure
While the Fontan operation improves survival for patients with a functional single ventricle, complications like heart failure remain prevalent during follow-up, causing frequent hospitalizations and reduced quality of life.
- Conditions
- Fontan, Heart Failure, Dapagliflozin, Cardiovascular Diseases
- Trial name
- NCT07482943
- Testing
- Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy
- Where
- 2 sites in Hong Kong
- Volunteers
- 30 people
- Sponsor
- The University of Hong Kong
Type 2 Diabetes
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)
This study is a multicenter, randomized, open-label, parallel-group, semaglutide injection-controlled clinical trial. It aims to evaluate the non-inferiority of UBT251 Injection in glycemic control compared with Semaglutide…
- Trial name
- UNIGUIDE-2 (NCT07653477)
- Testing
- UBT251 Injection 2.0 mg group, UBT251 Injection 4.0 mg group, UBT251 Injection 6.0 mg group
- Where
- China
- Volunteers
- 956 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Acute Kidney Injury
The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease
Acute kidney disease (AKD) happens between 7 and 90 days after an initial kidney injury (AKI). This period is crucial because it can determine whether the condition worsens into chronic kidney disease (CKD).
- Trial name
- ESS-AKD (NCT06528405)
- Testing
- dapagliflozin, Other anti-diabetic drug or no anti-diabetic drug, empagliflozin
- Where
- Taiwan
- Volunteers
- 264 people
- Sponsor
- National Taiwan University Hospital
Diabetes Mellitus, Type 2
iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD)
The present study aims to evaluate the efficacy and safety of different combinations of oral antidiabetics in patients with inadequate glycemic control on metformin monotherapy.
- Trial name
- TRIAD (NCT06560333)
- Testing
- N0892
- Where
- Brazil
- Sponsor
- Eurofarma Laboratorios S.A.
Heart Failure
Finerenone Plus SGLT2 Inhibitors in Heart Failure
The goal of this clinical study is to evaluate whether adding finerenone to standard treatment with a sodium-glucose cotransporter-2 (SGLT2) inhibitor provides additional benefits in patients with heart failure.
- Trial name
- FIN-SGLT2-HF (NCT07351864)
- Testing
- Finerenone, dapagliflozine
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Mansoura University